Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04762550
Other study ID # 20-5414.0
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date March 8, 2021
Est. completion date January 1, 2022

Study information

Verified date February 2021
Source University Health Network, Toronto
Contact Justyna Bartoszko, MD MSc FRCPC
Phone 416-340-4800
Email justyna.bartoszko@uhn.ca
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a prospective observational study of 100 patients undergoing liver transplantation at a single centre. Thrombin generation and kinetics will be assessed using a novel point-of-care device, and compared to conventional measures of hemostasis as well as viscoelastic tests to pinpoint specific coagulation deficits and identify potential therapeutic targets. The clinical course of patients will be followed for major bleeding and transfusion outcomes.


Description:

Liver transplantation is the only curative option for end stage liver disease, but is associated with high morbidity and mortality. End stage liver disease is known to be accompanied by dysregulated coagulation, which is further exacerbated in the immediate perioperative period by transplantation, leading to both coagulopathic bleeding and thrombosis. Altered thrombin generation is thought to play a key role in the predisposition of these patients for both severe coagulopathic hemorrhage and life-threatening thromboembolic complications. Despite this, thrombin generation during the immediate transplant period in patients with end-stage liver disease is poorly characterized, in part because it is not well reflected by conventional measures of coagulation. This study aims to characterize changes in thrombin generation capacity pre, intra- and post-transplant utilizing a novel point-of-care thrombin generation assay. Other specific aims of the study are to identify risk factors for patients with impaired thrombin generation and will assess the association of impaired thrombin generation with overall clinical bleeding risk. The overarching goal of this work is to develop a point-of-care-testing guided algorithm addressing dysregulated thrombin formation that improves coagulation management without increasing the risk of thromboembolic complications. Ultimately, this line of research will improve the outcomes of liver transplantation.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date January 1, 2022
Est. primary completion date January 1, 2022
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - All adult patients (> 18 years of age) proceeding to imminent (within 24 hours) liver transplantation surgery at Toronto General Hospital will be offered participation. - Patients should have end stage liver disease necessitating transplantation. All etiologies of end stage liver disease will be accepted. Exclusion Criteria: - Patients who are unable to consent to the study or who refuse participation will be excluded.

Study Design


Locations

Country Name City State
Canada Toronto General Hospital - University Health Network Toronto Ontario

Sponsors (1)

Lead Sponsor Collaborator
University Health Network, Toronto

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Transfusion Outcomes - Red Blood Cells The total number of red blood cells transfused From intra-operatively to within 12 hours post-operatively
Other Transfusion Outcomes - Platelets The total number of platelet units transfused From intra-operatively to within 12 hours post-operatively
Other Transfusion Outcomes - Frozen Plasma The total number of frozen plasma units transfused From intra-operatively to within 12 hours post-operatively
Other Transfusion Outcomes - Prothrombin Complex Concentrate The total number of units transfused From intra-operatively to within 12 hours post-operatively
Other Transfusion Outcomes - Fibrinogen Concentrate The total number of grams of fibrinogen transfused From intra-operatively to within 12 hours post-operatively
Other Bleeding Outcomes - Delayed Abdominal Closure Clinical bleeding outcome such as delayed abdominal From intra-operatively to within 12 hours post-operatively
Other Bleeding Outcomes - Return to the Operating Room for Re-Exploration Clinical bleeding outcome such as return to the operating room for re-exploration or evacuation of hematoma From intra-operatively to within 12 hours post-operatively
Primary Thrombin Generation - Endogenous Thrombin Potential (nM*min) The change in thrombin generation will be measured in patients undergoing liver transplantation, as assessed through the Endogenous Thrombin Potential (nM*min) The pattern of change in thrombin generation will be assessed intra-operatively at baseline through to study completion up to 12 hours post-operatively
Primary Thrombin Generation - Lag Time (Seconds) The change in thrombin generation will be measured in patients undergoing liver transplantation as assessed by the Lag Time (Seconds) The pattern of change in thrombin generation will be assessed intra-operatively at baseline through to study completion up to 12 hours post-operatively
Primary Thrombin Generation - Time to Peak (Seconds) The change in thrombin generation will be measured in patients undergoing liver transplantation by the Time to Peak (Seconds) The pattern of change in thrombin generation will be assessed intra-operatively at baseline through to study completion up to 12 hours post-operatively
Primary Thrombin Generation - Peak Height (nM) The change in thrombin generation will be measured in patients undergoing liver transplantation by the Peak Height (nM) The pattern of change in thrombin generation will be assessed intra-operatively at baseline through to study completion up to 12 hours post-operatively
Secondary Conventional Hemostatic Tests - Platelet Count The platelet count from the complete blood count in x10^9/L The pattern of change will be assessed intra-operatively at baseline through to study completion up to 12 hours post-operatively
Secondary Conventional Hemostatic Tests - INR The international normalized ratio (INR) in seconds The pattern of change will be assessed intra-operatively at baseline through to study completion up to 12 hours post-operatively
Secondary Conventional Hemostatic Tests - aPTT The activated partial thromboplastin time (aPTT) in seconds The pattern of change will be assessed intra-operatively at baseline through to study completion up to 12 hours post-operatively
Secondary Conventional Hemostatic Tests - Fibrinogen Level The Clauss Fibrinogen level in g/L The pattern of change will be assessed intra-operatively at baseline through to study completion up to 12 hours post-operatively
Secondary Viscoelastic Testing Rotational thromboelastometry (ROTEM) The pattern of change will be assessed intra-operatively at baseline through to study completion up to 12 hours post-operatively
See also
  Status Clinical Trial Phase
Completed NCT04180735 - Intestinal Perforation in Patients Receiving an Orthtopic Liver Transplantation in the Montpellier University Hospital
Completed NCT01011205 - Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver Transplantation Phase 3
Completed NCT01888432 - Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants Phase 3
Recruiting NCT04203004 - HOPE With Cytokine Filtration in Liver Transplantation (Cyto-HOPE) N/A
Recruiting NCT04564313 - Safety and Efficacy of Camrelizumab (Anti-PD-1 Antibody) in Recurrent HCC After Liver Transplantation Phase 1
Withdrawn NCT03596970 - Study of the Effect of Everolimus Immunosuppressive Combination Therapies on Renal Function When Used as a Maintenance Treatment for Liver Transplant Patients. Phase 3
Not yet recruiting NCT02544906 - Propofol Versus Dexmedetomidine for Prevention of Sevoflurane Agitation in Recipients of Living Donor Liver Transplantation N/A
Completed NCT03133065 - Early Treatment of Recurrent HCV- Infection Post Liver Transplantation in the Era of DAAs Phase 4
Recruiting NCT01705015 - Organ Transplantation Rehabilitation: Effect of Bedside Exercise Device and Activity Reinforcement N/A
Terminated NCT01445236 - Pilot Study of Immunosuppression Drug Weaning in Liver Recipients Exhibiting Biomarkers of High Likelihood of Tolerance N/A
Completed NCT01425385 - Autoregulation Assessment During Liver Transplantation N/A
Completed NCT01655563 - Pharmacogenetic Trial of Tacrolimus After Pediatric Transplantation Phase 2
Completed NCT00938860 - Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C Phase 4
Completed NCT00531921 - Effects of Donor and Recipient Genetic Expression on Heart, Lung, Liver, or Kidney Transplant Survival N/A
Completed NCT00456235 - Reduction in the Risk of Rejection by Mycophenolate Mofetil Dose Adjustment in Liver Transplant Patients With Side Effects Caused by the Calcineurine Inhibitors Phase 4
Terminated NCT00585858 - Cytokine Kinetics Test to Assess the Presence or Absence of Tolerance in Organ Transplant N/A
Withdrawn NCT00585429 - Evaluation of Kidney Disease in Liver Transplant Recipients N/A
Recruiting NCT00147459 - Immunogenicity of Booster Hepatitis B Vaccines in Children After Liver Transplantation N/A
Terminated NCT00161356 - Ambisome in Liver Transplant Patients Phase 4
Withdrawn NCT00167492 - Enteric Coated Myfortic for Liver Transplant Recipients Phase 4